Kim Sablich's most recent trade in Jazz Pharmaceuticals plc was a trade of 2,082 Ordinary Shares done at an average price of $129.7 . Disclosure was reported to the exchange on June 5, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals plc | Kim Sablich | EVP, GM of U.S. | Sale or transfer of securities back to the company at price $ 129.73 per share. | 05 Jun 2023 | 2,082 | 28,478 (0%) | 0% | 129.7 | 270,098 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Kim Sablich | EVP, GM of U.S., Commercial Ma | Sale of securities on an exchange or to another person at price $ 139.42 per share. | 08 Mar 2023 | 1,752 | 31,821 (0%) | 0% | 139.4 | 244,264 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Kim Sablich | EVP, GM of U.S., Commercial Ma | Sale of securities on an exchange or to another person at price $ 140.19 per share. | 08 Mar 2023 | 1,261 | 30,560 (0%) | 0% | 140.2 | 176,780 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Kim Sablich | EVP, GM of U.S., Commercial Ma | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 10,429 | 35,183 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Kim Sablich | EVP, GM of U.S., Commercial Ma | Payment of exercise price or tax liability using portion of securities received from the company at price $ 142.78 per share. | 03 Mar 2023 | 1,610 | 33,573 (0%) | 0% | 142.8 | 229,876 | Ordinary Shares |
| Eiger BioPharmaceuticals Inc | Kim Sablich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 28,000 | 28,000 | - | - | Stock Option (Right to Buy) | |
| Jazz Pharmaceuticals plc | Kim Sablich | EVP & GM, North America | Payment of exercise price or tax liability using portion of securities received from the company at price $ 149.25 per share. | 06 Jun 2022 | 1,759 | 28,583 (0%) | 0% | 149.3 | 262,531 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Kim Sablich | EVP & GM, North America | Sale of securities on an exchange or to another person at price $ 152.15 per share. | 06 Jun 2022 | 1,388 | 27,195 (0%) | 0% | 152.1 | 211,184 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Kim Sablich | EVP & GM, North America | Sale of securities on an exchange or to another person at price $ 151.87 per share. | 06 Jun 2022 | 1,317 | 24,855 (0%) | 0% | 151.9 | 200,016 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Kim Sablich | EVP & GM, North America | Sale of securities on an exchange or to another person at price $ 150.68 per share. | 06 Jun 2022 | 573 | 26,172 (0%) | 0% | 150.7 | 86,337 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Kim Sablich | EVP & GM, North America | Sale of securities on an exchange or to another person at price $ 149.22 per share. | 06 Jun 2022 | 250 | 26,745 (0%) | 0% | 149.2 | 37,306 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Kim Sablich | EVP & GM, North America | Sale of securities on an exchange or to another person at price $ 148.21 per share. | 06 Jun 2022 | 200 | 26,995 (0%) | 0% | 148.2 | 29,642 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Kim Sablich | EVP & GM, North America | Sale of securities on an exchange or to another person at price $ 152.59 per share. | 06 Jun 2022 | 101 | 24,754 (0%) | 0% | 152.6 | 15,412 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Kim Sablich | EVP & GM, North America | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 9,953 | 31,088 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Kim Sablich | EVP & GM, North America | Payment of exercise price or tax liability using portion of securities received from the company at price $ 153.96 per share. | 03 Mar 2022 | 746 | 30,342 (0%) | 0% | 154.0 | 114,854 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Kim Sablich | EVP & GM, North America | Sale of securities on an exchange or to another person at price $ 135.01 per share. | 11 Nov 2021 | 2,748 | 21,135 (0%) | 0% | 135.0 | 371,000 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Kim Sablich | EVP & GM, North America | Payment of exercise price or tax liability using portion of securities received from the company at price $ 176.47 per share. | 05 Jun 2021 | 1,452 | 23,883 (0%) | 0% | 176.5 | 256,234 | Ordinary Shares |
| Eiger BioPharmaceuticals Inc | Kim Sablich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Apr 2021 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Jazz Pharmaceuticals plc | Kim Sablich | EVP & GM, North America | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 8,535 | 25,335 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Kim Sablich | EVP & GM, North America | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2020 | 38,856 | 38,856 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jazz Pharmaceuticals plc | Kim Sablich | EVP & GM, North America | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2020 | 16,800 | 16,800 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Kim Sablich | EVP & GM, North America | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2020 | 3,144 | 3,144 | - | - | Incentive Stock Option (right to buy) |